细胞因子介导的CAR T治疗在AML中的耐药性
Anand S Bhagwat1,2, Leonel Torres2,3, Olga Shestova2
1Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Nature medicine
|September 27, 2024
概括
对急性髓性白血病 (AML) 的自主抗CD123CAR T细胞疗法是可行的,但有效性有限. 一种独特的抵抗机制,涉及骨髓支持细胞因子,阻碍了治疗的成功,这表明需要组合疗法.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 急性髓性白血病 (AML) 具有重大治疗挑战,特别是在复发或耐火病例中.
- 化学抗原受体 (CAR) T细胞疗法在B细胞恶性瘤中取得了显著的成功,但在AML中有效性有限.
研究的目的:
- 评估对复发性或耐药性AML的成年人进行自身抗CD123CAR T细胞治疗的可行性和疗效.
- 调查阻力机制限制CAR T细胞治疗在AML中的有效性.
主要方法:
- 一项试点研究涉及12名患有复发性或耐药性AML的成年人,他们接受了与自身抗CD123CAR T细胞治疗.
- 评估了制造成功率,细胞因子释放综合征发生率和临床反应.
- 分析了耐药性机制,包括细胞因子介导的AML爆发生存率和CAR T细胞耗尽.
主要成果:
- 在90.4%的运行中,成功制造了CAR T细胞.
- 细胞因子释放综合征发生在83.3%的患者中,25%的患者获得了临床反应.
- 在治疗期间分泌的骨髓支持细胞因子通过激酶信号促进AML爆发性存活,导致CAR T细胞耗尽.
结论:
- 自主抗CD123CAR T细胞疗法可用于AML,但与高率的细胞因子释放综合征和适度的临床疗效相关.
- 治疗诱导的细胞因子代表了一个独特的AML耐药性机制.
- 将CAR T细胞疗法与细胞因子信号传递抑制剂相结合可能会改善AML的结果.
更多相关视频
09:12Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
Published on: June 14, 2024
830
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.3K
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy
489
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
489
